Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
| Autor: | Brandt-Jacobsen, Niels H., Johansen, Marie Louise, Rasmussen, Jon, Forman, Julie L., Holm, Maria Refsgaard, Faber, Jens, Rossignol, Patrick, Schou, Morten, Kistorp, Caroline * |
|---|---|
| Zdroj: | In Diabetes & Metabolism July 2021 47(4) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect